18,717 Bristol Myers Squibb Company $BMY Shares Purchased by Profund Advisors LLC

Posted by Geri Gentry on Nov 2nd, 2026

Profund Advisors LLC raised its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 68.6% during the third quarter, Holdings Channel reports. The institutional investor owned 46,019 shares of the biopharmaceutical company’s stock after buying an additional 18,717 shares during the quarter. Profund Advisors LLC’s holdings in Bristol Myers Squibb were worth $2,872,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. ProShare Advisors LLC lifted its position in Bristol Myers Squibb by 1.5% during the 3rd quarter. ProShare Advisors LLC now owns 340,113 shares of the biopharmaceutical company’s stock valued at $21,223,000 after purchasing an additional 4,916 shares during the period. Vise Technologies Inc. grew its position in shares of Bristol Myers Squibb by 4.7% during the 3rd quarter. Vise Technologies Inc. now owns 148,608 shares of the biopharmaceutical company’s stock worth $9,273,000 after buying an additional 6,695 shares during the period. Investment Partners LTD. grew its position in shares of Bristol Myers Squibb by 53.3% during the 3rd quarter. Investment Partners LTD. now owns 19,162 shares of the biopharmaceutical company’s stock worth $1,196,000 after buying an additional 6,665 shares during the period. Summit Global Investments lifted its holdings in Bristol Myers Squibb by 5.8% in the third quarter. Summit Global Investments now owns 25,044 shares of the biopharmaceutical company’s stock valued at $1,563,000 after buying an additional 1,364 shares during the period. Finally, MGO One Seven LLC boosted its stake in Bristol Myers Squibb by 5.1% in the third quarter. MGO One Seven LLC now owns 42,221 shares of the biopharmaceutical company’s stock valued at $2,635,000 after acquiring an additional 2,037 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. TD Cowen started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating on the stock. Daiwa Securities Group lifted their price objective on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Cantor Fitzgerald dropped their price objective on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, October 8th. Finally, Rothschild & Co Redburn increased their target price on Bristol Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $65.46.

Get Our Latest Research Report on Bristol Myers Squibb

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

BMY stock opened at $62.46 on Monday. The business’s 50-day moving average price is $62.80 and its two-hundred day moving average price is $59.94. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. The firm has a market cap of $127.67 billion, a PE ratio of 13.85, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 1-year low of $45.20 and a 1-year high of $68.64.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same period in the previous year, the firm earned $1.63 earnings per share. The company’s revenue was up 6.9% on a year-over-year basis. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.40 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s payout ratio is currently 55.88%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.